Literature DB >> 10883468

The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case.

Y Tanaka1, H Funahashi, T Imai, T Naruse, K Suzumura, Y Oda.   

Abstract

We report herein the case of an 80-year-old woman with insulinoma who was regarded as an unsuitable candidate for immediate surgery due to her advanced age and obesity, for whom octreotide, a long-acting analogue of somatostatin, was used to improve her hypoglycemia and hyperinsulinemia without hyperalimentation. Administering a minimal dose of octreotide for a long period resulted in the improvement of leg edema, weight control, and cardiopulmonary function, and resection of the pancreatic tumor was safely carried out without any complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883468     DOI: 10.1007/s005950070124

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours.

Authors:  P Jaïs; B Terris; P Ruszniewski; M LeRomancer; F Reyl-Desmars; C Vissuzaine; G Cadiot; M Mignon; M J Lewin
Journal:  Eur J Clin Invest       Date:  1997-08       Impact factor: 4.686

2.  Involvement of MAP kinase and c-fos signaling in the inhibition of cell growth by somatostatin.

Authors:  H Yoshitomi; Y Fujii; M Miyazaki; N Nakajima; N Inagaki; S Seino
Journal:  Am J Physiol       Date:  1997-05

3.  The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.

Authors:  O Kisker; D Bartsch; R J Weinel; K Joseph; U H Welcke; F Zaraca; M Rothmund
Journal:  J Am Coll Surg       Date:  1997-05       Impact factor: 6.113

4.  Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.

Authors:  B Glaser; A Rösler; Y Halperin
Journal:  Isr J Med Sci       Date:  1990-01

5.  Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin).

Authors:  C D Stehouwer; W F Lems; H R Fischer; W H Hackeng; M A Naafs
Journal:  Acta Endocrinol (Copenh)       Date:  1989-07

6.  Malignant insulinoma causing liver metastasis 8 years after the initial surgery: report of a case.

Authors:  N Sata; W Kimura; T Kanazawa; T Muto
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

7.  Response of human insulinoma cells to extracellular calcium is different from normal B cells.

Authors:  M Kato; R Doi; M Imamura; N Okada; Y Shimada; R Hosotani; J I Miyazaki
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 8.  Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I.

Authors:  M Mignon; P Ruszniewski; P Podevin; L Sabbagh; G Cadiot; D Rigaud; S Bonfils
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Metabolic remission with octreotide in patients with insulinoma.

Authors:  F E von Eyben; E Grodum; H J Gjessing; C Hagen; H Nielsen
Journal:  J Intern Med       Date:  1994-03       Impact factor: 8.989

10.  Multiple endocrine neoplasia type 1 presenting as insulinoma, gastrinoma, and postbulbar duodenal ulcers: report of a case.

Authors:  S Murakami; A Satomi; K Ishida; M Matsuki; H Koda; S Miura
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

  10 in total
  2 in total

Review 1.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 2.  Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Authors:  Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-07       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.